Aclaris Therapeutics Inc (ACRS) — Cash Flow-to-Debt Ratio
Aclaris Therapeutics Inc (ACRS) has a Cash Flow-to-Debt Ratio of -0.20x as of September 2025, meaning its operating cash flow of $-10.93 Million could theoretically repay 0% of its total liabilities ($55.43 Million) in one year. Explore Aclaris Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aclaris Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Aclaris Therapeutics Inc across 12 annual periods. Also explore Aclaris Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Aclaris Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Aclaris Therapeutics Inc. For market capitalisation and broader financial context, see Aclaris Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-20.07 Million | $64.77 Million | ▲ +84.1% |
| 2023 | -1.95x | $-78.33 Million | $40.23 Million | ▼ -64.2% |
| 2022 | -1.19x | $-67.57 Million | $56.98 Million | ▼ -22.5% |
| 2021 | -0.97x | $-52.13 Million | $53.87 Million | ▲ +17.0% |
| 2020 | -1.17x | $-38.63 Million | $33.13 Million | ▲ +65.7% |
| 2019 | -3.40x | $-96.44 Million | $28.39 Million | ▼ -103.7% |
| 2018 | -1.67x | $-100.81 Million | $60.44 Million | ▲ +44.3% |
| 2017 | -3.00x | $-54.66 Million | $18.25 Million | ▲ +42.9% |
| 2016 | -5.25x | $-34.60 Million | $6.59 Million | ▲ +59.9% |
| 2015 | -13.10x | $-20.37 Million | $1.55 Million | ▼ -6441.3% |
| 2014 | -0.20x | $-7.64 Million | $38.13 Million | ▲ +4.9% |
| 2013 | -0.21x | $-4.92 Million | $23.37 Million | — |